AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05247658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic lens alone
Description: Therapeutic lens will be apposed on patient's dominant eye after bilateral PRK. Therapeutic lens will be maintained without interruption until the first postoperative visit when it will be removed by the surgeon.
Study NCT05247658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic lens + amniotic membrane (Visio-AMTRIX)
Description: Amniotic membrane (Visio-AMTRIX) will be apposed under therapeutic lens on patient's non-dominant eye after bilateral PRK. Amniotic membrane and therapeutic lens will be maintained without interruption until the first postoperative visit when it will be removed by the surgeon.
Study NCT05357755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally as delayed release tablets.
Study NCT05357755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally as delayed release tablets.
Study NCT06008860 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Experimental: Primary Cohort
Description: Astepro (azelastine) is a second generation antihistamine, as well as an anti-inflammatory and mast cell stabilizer8. It is available as a 0.1% and 0.15% nasal spray by prescription in the USA and over-the-counter in the European Union (EU). Dosing for adults and adolescents 12 years and older is 1 or 2 sprays per nostril twice daily (0.1%) or 2 sprays per nostril once daily (0.15%)9. It is approved by the FDA for treatment of seasonal allergic rhinitis symptoms (rhinorrhea, sneezing, and nasal pruritus) in adults and children 2 years and older, perennial allergic rhinitis in adults and children ages 6 months and older, and the symptoms of vasomotor rhinitis (rhinorrhea, nasal congestion and postnasal drip) in adults and adolescents 12 years and older9.
Study NCT06008860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Primary Cohort - Placebo
Description: A Placebo will be provided by Bayer which features similar color and packaging as azelastine.
Study NCT06650592 — intervention group
Intervention type: OTHER
Intervention: All patients who were candidates for immediate lymphatic reconstruction (ILR)
Description: All patients who were candidates for immediate lymphatic reconstruction (ILR)
Study NCT05284890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99677
Description: Specified dose on specified days
Study NCT05548556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive subcutaneous (SC) placebo every 4 weeks (Q4W)
Study NCT05548556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7204239
Description: Participants will receive SC RO7204239 Q4W
Study NCT04770961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane catheter with 0.5% Ropivacaine
Description: Ultrasound guided, right sided, ESP catheter inserted at the level of T5. 20 cc injection of 0.5% Ropivacaine is injected at the time of catheter placement. Postoperatively, a programmed intermittent bolus infusion of 0.2% Ropivacaine will be delivered via the ESP catheter.
Study NCT04770961 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Erector spinae plane catheter with saline
Description: Ultrasound guided, right sided, ESP catheter inserted at the level of T5. 20 cc injection of saline is injected at the time of catheter placement. Postoperatively, a programmed intermittent bolus infusion of saline will be delivered via the ESP catheter.
Study NCT06287905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin Oral Tablet
Description: 1-Dose and administration of prazosin: 30 μg/kg/dose of prazosin will be delivered orally every 6 hours 4 doses, in adults we shouldn't exceed 1 mg per dose. Prazosin will be delivered using a nasogastric tube while securing the patient's airway in the event of vomiting or unconsciousness. Every 30 minutes for the first three hours, every hour for the following six, and then every four hours until improvement, blood pressure, pulse rate, respiration rate, and oxygen saturation will be measured. When pain is the only symptom, prophylaxis shouldn't be given. To avoid the first-dose phenomenon, the patient should remain in a laying position for around 3 hours (even while the case is being examined) (Shoreit et al., 2019).
Study NCT05346692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete Survey
Study NCT05346692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Complete Interview
Study NCT05346692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Complete mindfulness intervention
Study NCT05346692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Complete interview
Study NCT06548880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured exercise program
Description: The intervention applied in this research has an online exercise training conducting with a structured exercise program including different types of exercise which are range of motion, stretching and low intensity aerobic exercises. The exercise program continued with sessions each lasting 60 minutes, once a week for 10 weeks.
Study NCT05388669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib tablets will be administered orally.
Study NCT05388669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)
Description: Amivantamab injection will be administered subcutaneously by manual injection.
Study NCT05388669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab Intravenous
Description: Amivantamab will be administered by IV infusion.
Study NCT06504394 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (+) Berahyaluronidase alfa
Description: SC injection
Study NCT06656052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1. working memory task.
Description: Arithmetic test (Backward counting with serial 3 subtraction and articulation): participants will be asked to count out loud backward with serial subtraction of 3 from each number, starting with a random number provided by the researcher.
Study NCT06656052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2. Visual and Verbal Fluency Task
Description: Stroop colour word test (modified Stroop test): participants will be asked to name the colour of ink that each word is printed in. This test will appear on the mobile phone in their hands while they walk to increase the effect of cognitive loading.
Study NCT06656052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3. Motor Task
Description: Participants will be asked to hold a tray of glasses filled with water and walk 10 meters to calculate the effect of cognitive loading on gait.
Study NCT06615518 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transforaminal endoscopic lumbar discectomy
Description: FELD is a minimally invasive spine surgery technique performed through small incisions using an endoscope. The procedure involves accessing the herniated disc through either the transforaminal (TELD) or interlaminar (IELD) approach, depending on the location of the disc herniation. The endoscopic approach allows for direct visualization of the affected area using a camera, and specialized instruments are used to remove the herniated portion of the disc.~What distinguishes this intervention:~* Small incisions (typically \&amp;lt;1 cm) result in less soft tissue damage compared to traditional open surgery.~* Real-time endoscopic visualization allows for precise disc removal and reduced trauma to surrounding structures such as muscles and ligaments.~* Minimized postoperative pain and faster recovery times due to the less invasive nature of the procedure.~* Outpatient or short hospital stay is often possible, contributing to faster patient discharge.
Study NCT06615518 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interlaminar endoscopic lumbar discectomy
Description: FELD is a minimally invasive spine surgery technique performed through small incisions using an endoscope. The procedure involves accessing the herniated disc through either the transforaminal (TELD) or interlaminar (IELD) approach, depending on the location of the disc herniation. The endoscopic approach allows for direct visualization of the affected area using a camera, and specialized instruments are used to remove the herniated portion of the disc.~What distinguishes this intervention:~* Small incisions (typically \&amp;lt;1 cm) result in less soft tissue damage compared to traditional open surgery.~* Real-time endoscopic visualization allows for precise disc removal and reduced trauma to surrounding structures such as muscles and ligaments.~* Minimized postoperative pain and faster recovery times due to the less invasive nature of the procedure.~* Outpatient or short hospital stay is often possible, contributing to faster patient discharge.
Study NCT06615518 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microdiscectomy
Description: Microdiscectomy is a conventional surgical technique for treating lumbar disc herniation, involving a small open incision. In this procedure, the surgeon makes an incision typically between 2-3 cm in length, then uses an operating microscope to gain magnified visualization of the herniated disc. The surgeon removes part of the lamina (laminotomy) to access the disc and nerves. Special instruments are used to remove the herniated portion of the disc that is compressing the spinal nerves, relieving symptoms such as pain, numbness, and weakness.~What distinguishes this intervention:~* Larger incision (2-3 cm) compared to FELD, but still smaller than traditional open discectomy, allowing better visualization.~* Microscopic magnification allows precise removal of disc material while minimizing trauma to surrounding neural structures.~* Direct access to the affected area via the removal of part of the lamina (laminotomy), offering a well-established and highly effective approach to reli
Study NCT05629884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPERIA-REHAB
Description: After the randomization of the patient there will be some preliminary sessions where the means of self-monitoring training and the Borg 1/10 effort scale will be explained and training videos will be shown. Doubts will also be answered.~Afterwards, training will start through the COPERIA-REHAB platform, which will last 8 weeks (6 days per week).
Study NCT05270005 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound-based flow imaging
Description: Ultrasound-based flow imaging of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
Study NCT05270005 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound-based strain imaging
Description: Ultrasound-based strain imaging of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
Study NCT05270005 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional duplex
Description: Conventional duplex measurements of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
Study NCT05381766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSA Model
Description: Community-supported agriculture (CSA) involves a community of individuals who support a farm and in return receive distributions of the farm's produce throughout the growing season. Culturally appropriate produce will be provided weekly for 20 weeks to community members in Sunset Park and surrounding neighborhoods. Brooklyn Grange in Sunset Park will grow and provide Chinese specific produce for a fee ranging from $7 to $31 depending on the participant's self-identified situation and Angel Family Farm will grow and provide Mexican specific produce for a fee of up to $15. Participants that receive SNAP benefits can use their EBT card to cover their produce box fees. Education will be offered in the form of nutrition education, cooking tutorials, and farming information provided by staff at Brooklyn Grange.
Study NCT05916664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kinto Care Coaching
Description: Describe the basics of the intervention
Study NCT05706337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol 1-2mg / kg was for anesthesia induction. Propofol is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus.
Study NCT05706337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: Ciprofol 0.2～0.5mg/kg was for anesthesia induction. Ciprofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthetic induction and maintenance agents include rapid induction of general anesthesia, rapid return of consciousness, minimal residual effects on the central nervous system and less injection pain.
Study NCT05405725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ENZ215
Description: Enrolled women with postmenopausal osteoporosis will receive ENZ215 (60mg)
Study NCT05405725 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolia
Description: Enrolled women with postmenopausal osteoporosis will receive Prolia
Study NCT04732195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pilocarpine microneedle patch
Description: Each microneedle (MN) patch contains an array of solid, water-soluble, micron-scale needles that encapsulate the medication (Pilocarpine). The patch form can be placed directly on the skin.
Study NCT04732195 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine Iontophoresis
Description: Pilocarpine Iontophoresis is a process of transdermal pilocarpine delivery by use of a voltage gradient on the skin. An agar gel disc containing pilocarpine is placed under the electrodes which are connected to the Macroduct 3700 Sweat Inducer device.
Study NCT05266430 — intervention group
Intervention type: OTHER
Intervention: Standard of Care
Description: Patients who are planned to receive plaque radiotherapy for the treatment of IL/CM based on the expert judgment of the investigator
Study NCT05266430 — intervention group
Intervention type: DRUG
Intervention: AU-011
Description: Previously received
Study NCT05741437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-378, QD, PO Drug: D745, D150, QD, PO
Description: Durg: CKD-378, QD, PO Drug: D745, D150, QD, PO
Study NCT05471817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Capsule, oral, single dose
Study NCT05471817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Capsule, oral, single dose
Study NCT05233163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin 10 mg oral daily for 12 weeks
Study NCT06625515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-559
Description: DHX9 tablets will be taken orally
Study NCT06761066 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NVP-NK4146
Description: BID for 36 weeks orally
Study NCT06761066 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NVP-NK4146 Placebo
Description: BID for 36 weeks orally
Study NCT06774183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Near vision glasses for presbyopia correction
Description: Provision of near vision glasses for presbyopia correction to individuals who did not previously have glasses and have correctable presbyopia
Study NCT06773247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I. Myofascial Release Technique ,Cupping Technique and II. Conventional Physical Therapy
Description: The cupping procedure was performed as follows: Massage oil was applied over the area first to improve contact and makes it easier to move the cup's position. double-walled glass cups (6 glasses with diameters from 75 to 100 mm) were held inverted, after which each glass was placed on an afflicted area overlying the low back muscle (acupoint: BL23).~Myofascial Release Technique Vertical stroking technique was performed in lumbar region to quadratus lumborum. AIt was performed as follow; Quadratus lumborum is palpated in prone and side lying for trigger points. The technique is applied by the patient positioned in side lying with a pillow under waist to exaggerate stretch of the muscle. The therapist stands at level of patient's hip posterior and counter pre
Study NCT06771258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Light (PDT)
Description: Red LED light
Study NCT06773624 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PET/CT-enterography with 68Ga-DOTATOC
Description: Patients underwent to PET/CT-enterography with 68Ga-DOTATOC
Study NCT06774456 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: instrumented 3D serious game (BE API 3.0)
Description: It is composed of bimanual tasks integrated into a game scenario. The child is first equipped with markers on the upper limb (UL) and trunk (3D motion analysis and electromyography), and he/she can then play the game. There are several tasks ('piloting missions') to evaluate specific UL movements. The UL movements are recorded when the child is playing. The instruments of the set-up (wheel, turbo, etc.) are connected to the game to play and can also be used as measurements (grip strength, etc.). The markers are then removed. The total duration of the game is about 30-45 minutes, including placing/removing markers and the game.
Study NCT06771284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Function-based assessment and intervention
Description: This intervention will be implemented by the caregiver. The intervention will consist of teaching the child an alternative, appropriate skill (usually communication) to replace the problem behavior. The caregiver will provide reinforcement for the appropriate skill and no reinforcement (i.e., extinction) following problem behavior. The caregiver will also learn and use general strategies for teaching social-emotional skills (e.g., setting appropriate rules) as part of the intervention.
Study NCT06772272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) used to treat anemia. Participants in the Roxadustat group will receive 100mg of Roxadustat orally three times per week for three weeks (two weeks prior to surgery and one week post-surgery). The dosage may be adjusted based on hemoglobin levels during the perioperative period: if hemoglobin rises above 150g/L, the drug will be stopped; if hemoglobin increases by more than 20g/L from baseline but is still below 130g/L, the dosage will be reduced to 70mg; if hemoglobin drops by more than 20g/L from baseline, the dosage will be increased to 120mg.
Study NCT06774976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8-week Evidence-Based Neck Resistance Training Program
Description: See arm/group description.
Study NCT06775080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol (beta-blocker used treat high blood pressure)
Description: Enrolled patients began receiving propranolol alone orally twice daily (10 mg bid) 10-14 days prior to surgery, and after 3 days of treatment, the dose of propranolol was increased to 20 mg bid daily until the day of surgery if the following three predefined criteria were met: systolic blood pressure greater than 90 mmHg, heart rate greater than 60 bpm, and no significant symptoms (e.g., syncope, insomnia, fatigue). The patient continues to be treated from 1 week after surgery.From 1 week after surgery, patients continue propranolol for 3 weeks. Patients will be monitored daily for symptoms, blood pressure, and heart rate and will be followed for observation at 6, 12, and 24 months after surgery until disease progression or clinical death, unless intolerable toxicity occurs and the patient refuses to continue treatment. The efficacy and safety of the preoperative propranolol β-blockade regimen in patients with gastrointestinal tract tumors was evaluated using the study objectives in S
Study NCT06772701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Mini International Neuropsychiatric Interview
Description: Fathers have Mini International Neuropsychiatric Interview, the standard diagnostic tool for post-natal depression
Study NCT06772701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EPDS book
Description: PH-Q9, EPDS and socio-demographic questionnaires are completed online at inclusion and 6 to 8 weeks after the birth of child.
Study NCT06772701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EPDS book
Description: PH-Q9, EPDS and socio-demographic questionnaires are completed online at inclusion and 6 to 8 weeks after the birth of child.
Study NCT06771908 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Conjunctival Swab
Description: CFU/ml by bacterial species before and after prophylaxis.
Study NCT06773195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: There are 3 planned dose levels of ulixertinib(450 mg BID, 300 mg BID, or 150 mg BID)
Study NCT06773195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib for 28 day cycles.
Study NCT06772103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: self-locking biceps tenodesis
Description: The LHB tendon is detached from its origin at the level of the superior labrum. This technique supports the self-locking mechanism of the LHB tendon in the bicipital groove by detaching the tendon from the Y-shaped superior glenoid, including the superior labrum. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate subsequent localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).